期刊论文详细信息
International Journal for Equity in Health
Global challenges of implementing human papillomavirus vaccines
Amrita Mishra2  Janice E Graham1 
[1] Department of Bioethics, Dalhousie University, Faculty of Medicine, 1459 Oxford Street, Halifax, Nova Scotia,B3H 4R2, Canada;Technoscience and Regulation Research Unit, 1459 Oxford Street, Halifax, Nova Scotia,B3H 4R2, Canada
关键词: gender;    equity;    immunization;    vaccine;    cervical cancer;    Human Papillomavirus;   
Others  :  829752
DOI  :  10.1186/1475-9276-10-27
 received in 2010-12-15, accepted in 2011-06-30,  发布年份 2011
PDF
【 摘 要 】

Human Papillomavirus vaccines are widely hailed as a sweeping pharmaceutical innovation for the universal benefit of all women. The implementation of the vaccines, however, is far from universal or equitable. Socio-economically marginalized women in emerging and developing, and many advanced economies alike, suffer a disproportionately large burden of cervical cancer. Despite the marketing of Human Papillomavirus vaccines as the solution to cervical cancer, the market authorization (licensing) of the vaccines has not translated into universal equitable access. Vaccine implementation for vulnerable girls and women faces multiple barriers that include high vaccine costs, inadequate delivery infrastructure, and lack of community engagement to generate awareness about cervical cancer and early screening tools. For Human Papillomavirus vaccines to work as a public health solution, the quality-assured delivery of cheaper vaccines must be integrated with strengthened capacity for community-based health education and screening.

【 授权许可】

   
2011 Graham and Mishra; licensee BioMed Central Ltd.

【 预 览 】
附件列表
Files Size Format View
20140714083547923.pdf 245KB PDF download
【 参考文献 】
  • [1]Koulova A, Tsui J, Irwin K, Van Damme P, Biellik R, Aguado MT: Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008. Vaccine 2008, 26:6529-41.
  • [2]National Advisory Committee on Immunization (NACI): Statement on Human Papillomavirus Vaccine. [http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/07pdf/acs33-02.pdf] webcite
  • [3]Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER, Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP): Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007, 56(RR-2):1-24.
  • [4]Foerster V, Murtagh J: Human papillomavirus (HPV) vaccines: a Canadian update. Issues Emerg Health Technol 2007, 109:1-8.
  • [5]Monie A, Hung CF, Roden R, Wu TC: Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer. Biologics 2008, 2:97-105.
  • [6]Centers for Disease Control and Prevention (CDC): FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the advisory committee on immunization practices (ACIP). Morbidity and Mortality Weekly Report (MMWR) 2010, 59:626-629.
  • [7]Centers for Disease Control and Prevention (CDC): FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report (MMWR) 2010, 59:630-2.
  • [8]Schiller JT, Castellsagué X, Villa LL, Hildesheim A: An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 2008, 26(Suppl 10):K53-61.
  • [9]Fisher R, Darrow DH, Tranter M, Williams JV: Human papillomavirus vaccine: recommendations, issues and controversies. Curr Opin Pediatr 2008, 20:441-5.
  • [10]Garland SM, Smith JS: Human papillomavirus vaccines: current status and future prospects. Drugs 2010, 70:1079-98.
  • [11]Frazer IH: Measuring serum antibody to human papillomavirus following infection or vaccination. Gynecol Oncol 2010, 118(Suppl 1):S8-11.
  • [12]FUTURE I/II Study Group, Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Joura EA, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Maansson R, Lu S, Vuocolo S, Hesley TM, Barr E, Haupt R: Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010, 341:c3493.
  • [13]Harper DM: Prevention of human papillomavirus infections and associated diseases by vaccination: a new hope for global public health. Public Health Genomics 2009, 12:319-30.
  • [14]Lowy DR, Solomon D, Hildesheim A, Schiller JT, Schiffman M: Human papillomavirus infection and the primary and secondary prevention of cervical cancer. Cancer 2008, 113(Suppl 7):1980-93.
  • [15]Wright TC, Van Damme P, Schmitt HJ, Meheus A: Chapter 14: HPV vaccine introduction in industrialized countries. Vaccine 2006, 24(Suppl 3):122-31.
  • [16]Lévy-Bruhl D, Bousquet V, King LA, O'Flanagan D, Bacci S, Lopalco PL, Salmaso S, country specific VENICE gate keepers and contact points: The current state of introduction of HPV vaccination into national immunisation schedules in Europe: results of the VENICE 2008 survey. Eur J Cancer 2009, 45:2709-13.
  • [17]International Monetary Fund: [http://www.imf.org/external/pubs/ft/weo/2010/01/weodata/groups.htm#oem] webciteWorld Economic Outlook Database--WEO Groups and Aggregates Information, Country Composition of WEO Groups.
  • [18]Agosti JM, Goldie SJ: Introducing HPV vaccine in developing countries--key challenges and issues. N Engl J Med 2007, 356:1908-10.
  • [19]Maybarduk P, Rimmington S: Compulsory Licenses: A Tool to Improve Global Access to the HPV Vaccine? Am J Law Med 2009, 35:323-350.
  • [20]Andrus JK, Sherris J, Fitzsimmons JW, Kane MA, Aguado MT: Introduction of human papillomavirus vaccines into developing countries - international strategies for funding and procurement. Vaccine 2008, 26(Suppl 10):K87-92.
  • [21]Padmanabhan S, Amin T, Sampat B, Cook-Deegan R, Chandrasekharan S: Intellectual property, technology transfer and manufacture of low-cost HPV vaccines in India. Nat Biotechnol 2010, 28:671-8.
  • [22]Graham J, Jones M: Rendre evident: une approche symetrique de la réglementation des produits thérapeutiques. (Determining evidence: a symmetrical approach to the regulation of therapeutic products.). Sociologie et sociétés 2010, 42:153-180.
  • [23]Erickson LJ, De Wals P, Farand L: An analytical framework for immunization programs in Canada. Vaccine 2005, 23:2470-6.
  • [24]Boutayeb A, Boutayeb S: The burden of non communicable diseases in developing countries. Int J Equity Health 2005, 4:2. BioMed Central Full Text
  • [25]Tsu VD: Overcoming barriers and ensuring access to HPV vaccines in low-income countries. Am J Law Med 2009, 35:401-13.
  • [26]WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre): Human Papillomavirus and Related Cancers in World. [http://apps.who.int/hpvcentre/statistics/dynamic/ico/SummaryReportsSelect.cfm] webciteSummary Report 2010.
  • [27]Muñoz N, Bosch FX, Castellsagué X, Díaz M, de Sanjose S, Hammouda D, Shah KV, Meijer CJ: Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004, 111:278-85.
  • [28]Franco EL, Harper DM: Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine 2005, 23:2388-94.
  • [29]Cutts FT, Franceschi S, Goldie S, Castellsague X, de Sanjose S, Garnett G, Edmunds WJ, Claeys P, Goldenthal KL, Harper DM, Markowitz L: Human papillomavirus and HPV vaccines: a review. Bull World Health Organ 2007, 85:719-26.
  • [30]Galani E, Christodoulou C: Human papilloma viruses and cancer in the post-vaccine era. Clin Microbiol Infect 2009, 15:977-81.
  • [31]Stanley M: Potential mechanisms for HPV vaccine-induced long-term protection. Gynecol Oncol 2010, 118(1 Suppl):S2-7.
  • [32]Sankaranarayanan R, Gaffikin L, Jacob M, Sellors J, Robles S: A critical assessment of screening methods for cervical neoplasia. Int J Gynaecol Obstet 2005, 89(Suppl 2):S4-S12.
  • [33]American Society for Colposcopy and Cervical Pathology: [http://www.asccp.org/pdfs/consensus/clinical_update_20090408.pdf] webciteHPV Genotyping Clinical Update.
  • [34]Jones BA, Davey DD: Quality management in gynecologic cytology using interlaboratory comparison. Arch Pathol Lab Med 2000, 124:672-81.
  • [35]Sankaranarayanan R, Bhatla N, Gravitt PE, Basu P, Esmy PO, Ashrafunnessa KS, Ariyaratne Y, Shah A, Nene BM: Human papillomavirus infection and cervical cancer prevention in India, Bangladesh, Sri Lanka and Nepal. Vaccine 2008, 26(Suppl 12):M43-52.
  • [36]Othman NH, Rebolj M: Challenges to cervical screening in a developing country: The case of Malaysia. Asian Pac J Cancer Prev 2009, 10:747-52.
  • [37]Tay SK, Ngan HY, Chu TY, Cheung AN, Tay EH: Epidemiology of human papillomavirus infection and cervical cancer and future perspectives in Hong Kong, Singapore and Taiwan. Vaccine 2008, 26(Suppl 12):M60-70.
  • [38]Scarinci IC, Garcia FA, Kobetz E, Partridge EE, Brandt HM, Bell MC, Dignan M, Ma GX, Daye JL, Castle PE: Cervical cancer prevention: new tools and old barriers. Cancer 2010, 116:2531-42.
  • [39]Manderson L, Hoban E: Cervical cancer services for Indigenous women: advocacy, community-based research and policy change in Australia. Women Health 2006, 43:69-88.
  • [40]Elkan R, Avis M, Cox K, Wilson E, Patel S, Miller S, Deepak N, Edwards C, Staniszewska S, Kai J: The reported views and experiences of cancer service users from minority ethnic groups: a critical review of the literature. Eur J Cancer Care 2007, 16:109-21.
  • [41]McDonald JT, Kennedy S: Cervical cancer screening by immigrant and minority women in Canada. J Immigr Minor Health 2007, 9:323-34.
  • [42]Johnson CE, Mues KE, Mayne SL, Kiblawi AN: Cervical cancer screening among immigrants and ethnic minorities: a systematic review using the Health Belief Model. J Low Genit Tract Dis 2008, 12:232-41.
  • [43]Amankwah E, Ngwakongnwi E, Quan H: Why many visible minority women in Canada do not participate in cervical cancer screening. Ethn Health 2009, 14:337-49.
  • [44]Ma GX, Toubbeh JI, Wang MQ, Shive SE, Cooper L, Pham A: Factors associated with cervical cancer screening compliance and noncompliance among Chinese, Korean, Vietnamese, and Cambodian women. J Natl Med Assoc 2009, 101:541-51.
  • [45]Samuel PS, Pringle JP, James NW, Fielding SJ, Fairfield KM: Breast, cervical, and colorectal cancer screening rates amongst female Cambodian, Somali, and Vietnamese immigrants in the USA. Int J Equity Health 2009, 8:30. BioMed Central Full Text
  • [46]ACOG Committee on Practice Bulletins--Gynecology: ACOG Practice Bulletin no. 109: Cervical cytology screening. Obstet Gynecol 2009, 114:1409-20.
  • [47]Clarke AE, Casper M: From simple technology to complex arena: classification of Pap smears, 1917-90. Med Anthropol Q 1996, 10:601-23.
  • [48]National Cancer Institute Workshop: The 1988 Bethesda System for reporting cervical/vaginal cytological diagnoses. JAMA 1989, 262:931-4.
  • [49]Report of the 1991 Bethesda workshop: The revised Bethesda System for reporting cervical/vaginal cytologic diagnoses. Acta Cytol 1992, 36:273-6.
  • [50]McLachlin CM, Mai V, Murphy J, Fung-Kee-Fung M, Chambers A, Oliver TK: Ontario cervical cancer screening clinical practice guidelines. J Obstet Gynaecol Can 2007, 29:344-53.
  • [51]Sawaya GF: Cervical-cancer screening-new guidelines and the balance between benefits and harms. N Engl J Med 2009, 361:2503-5.
  • [52]World Health Organization: Cytology screening. [http://www.who.int/cancer/detection/cytologyscreen/en/index.html] webcite
  • [53]Kitchener HC, Castle PE, Cox JT: Chapter 7: Achievements and limitations of cervical cytology screening. Vaccine 2006, 24:63-70.
  • [54]Franco EL, Coutlée F, Ferenczy A: Integrating human papillomavirus vaccination in cervical cancer control programmes. Public Health Genomics 2009, 12:352-61.
  • [55]Zhao FH, Lin MJ, Chen F, Hu SY, Zhang R, Belinson JL, Sellors JW, Franceschi S, Qiao YL, Castle PE, on behalf of Cervical Cancer Screening Group in China: Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China. Lancet Oncol 2010, in press.
  • [56]Sankaranarayanan R, Basu P, Wesley RS, Mahe C, Keita N, Mbalawa CC, Sharma R, Dolo A, Shastri SS, Nacoulma M, Nayama M, Somanathan T, Lucas E, Muwonge R, Frappart L, Parkin DM: Accuracy of visual screening for cervical neoplasia: Results from an IARC multicentre study in India and Africa. Int J Cancer 2004, 110:907-13.
  • [57]Chirenje ZM, Rusakaniko S, Kirumbi L, Ngwalle EW, Makuta-Tlebere P, Kaggwa S, Mpanju-Shumbusho W, Makoae L: Situation analysis for cervical cancer diagnosis and treatment in east, central and southern African countries. Bull World Health Organ 2001, 79:127-32. 18
  • [58]Boutayeb A: Developing countries and neglected diseases: challenges and perspectives. Int J Equity Health 2007, 6:20. BioMed Central Full Text
  • [59]Anorlu RI: Cervical cancer: the sub-Saharan African perspective. Reprod Health Matters 2008, 16:41-9.
  • [60]Hanna TP, Kangolle AC: Cancer control in developing countries: using health data and health services research to measure and improve access, quality and efficiency. BMC Int Health Hum Rights 2010, 10:24. BioMed Central Full Text
  • [61]Sankaranarayanan R, Thara S, Esmy PO, Basu P: Cervical cancer: screening and therapeutic perspectives. Med Princ Pract 2008, 17:351-64.
  • [62]Casper MJ, Carpenter LM: Sex, drugs, and politics: the HPV vaccine for cervical cancer. Sociol Health Illn 2008, 30:886-99.
  • [63]Colgrove J, Abiola S, Mello MM: HPV vaccination mandates--lawmaking amid political and scientific controversy. N Engl J Med 2010, 363:785-91.
  • [64]Haber G, Malow RM, Zimet GD: The HPV vaccine mandate controversy. J Pediatr Adolesc Gynecol 2007, 20:325-31.
  • [65]Aronowitz R: Gardasil: A Vaccine Against Cancer and a Drug to reduce risk. In Three shots at prevention: The HPV vaccine and the politics of medicine's simple solutions. 1st edition. Edited by Wailoo, K, Livingston J, Epstein S, Aronowitz R. Baltimore: Johns Hopkins University Press; 2010:21-38.
  • [66]Hunt A, Connell E: The HPV vaccination campaign: A project of moral regulation in an era of biopolitics. Can J Sociol 2010, 35:1. 63-82
  • [67]Phillips SP: Defining and measuring gender: A social determinant of health whose time has come. Int J Equity Health 2005, 4:11. BioMed Central Full Text
  • [68]Frazer I: Human Papillomaviruses. In Vaccines: A biography. Edited by Artenstein AW. New York: Springer; 2010.
  • [69]Tjalma WA, Arbyn M, Paavonen J, van Waes TR, Bogers JJ: Prophylactic human papillomavirus vaccines: the beginning of the end of cervical cancer. Int J Gynecol Cancer 2004, 14:751-61.
  • [70]Leggatt GR, Frazer IH: HPV vaccines: the beginning of the end for cervical cancer. Curr Opin Immunol 2007, 19:232-8.
  • [71]Zimet GD, Liddon N, Rosenthal SL, Lazcano-Ponce E, Allen B: Chapter 24: Psychosocial aspects of vaccine acceptability. Vaccine 2006, 24(Suppl 3):201-9.
  • [72]Habel MA, Liddon N, Stryker JE: The HPV vaccine: a content analysis of online news stories. J Womens Health (Larchmt) 2009, 18:401-7.
  • [73]Hughes J, Cates JR, Liddon N, Smith JS, Gottlieb SL, Brewer NT: Disparities in how parents are learning about the human papillomavirus vaccine. Cancer Epidemiol Biomarkers Prev 2009, 18:363-72.
  • [74]Kelly BJ, Leader AE, Mittermaier DJ, Hornik RC, Cappella JN: The HPV vaccine and the media: how has the topic been covered and what are the effects on knowledge about the virus and cervical cancer? Patient Educ Couns 2009, 77:308-13.
  • [75]Forster A, Wardle J, Stephenson J, Waller J: Passport to promiscuity or lifesaver: press coverage of HPV vaccination and risky sexual behavior. J Health Commun 2010, 15:205-17.
  • [76]Hilton S, Hunt K, Langan M, Bedford H, Petticrew M: Newsprint media representations of the introduction of the HPV vaccination programme for cervical cancer prevention in the UK (2005-2008). Soc Sci Med 2010, 70:942-50.
  • [77]Mah CL: Governing Immunization in Canada. [https:/ / tspace.library.utoronto.ca/ bitstream/ 1807/ 19058/ 1/ Mah_Catherine_L_200911_PhD_thesis.p df] webcitePhD Thesis University of Toronto, Department of Health Policy, Management and Evaluation; 2009, 138-145. [Chapters 7-8]
  • [78]Epstein S: The Great Undiscussable: HPV, Anal Cancer and Gay Men's Health. In Three shots at prevention: The HPV va ccine and the politics of medicine's simple solutions. 1st edition. Edited by Wailoo K, Livingston J, Epstein S, Aronowitz R. Baltimore: Johns Hopkins University Press; 2010:61-90.
  • [79]Mayer KH, Bradford JB, Makadon HJ, Stall R, Goldhammer H, Landers S: Sexual and gender minority health: what we know and what needs to be done. Am J Public Health 2008, 98:989-95.
  • [80]Crosbie EJ, Brabin L: Cervical cancer: problem solved? Vaccinating girls against human papillomavirus. BJOG 2010, 117:137-42.
  • [81]Adams M, Jasani B, Fiander A: Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening. Vaccine 2007, 25:3007-13.
  • [82]Howlett RI, Miller AB, Pasut G, Mai V: Defining a strategy to evaluate cervical cancer prevention and early detection in the era of HPV vaccination. Prev Med 2009, 48:432-7.
  • [83]Stanley M, Villa LL: Monitoring HPV vaccination. Vaccine 2008, 26(Suppl 1):A24-7.
  • [84]Bonanni P, Cohet C, Kjaer SK, Latham NB, Lambert PH, Reisinger K, Haupt RM: A summary of the post-licensure surveillance initiatives for Gardasil/Silgard. Vaccine 2010, 28:4719-30.
  • [85]Black AD, Car J, Pagliari C, Anandan C, Cresswell K, Bokun T, McKinstry B, Procter R, Majeed A, Sheikh A: The Impact of eHealth on the Quality and Safety of Health Care: A Systematic Overview. PLoS Med 2011, 8:e1000387.
  • [86]Heffernan ME, Garland SM, Kane MA: Global reduction of cervical cancer with human papillomavirus vaccines: insights from the hepatitis B virus vaccine experience. Sex Health 2010, 7:383-90.
  • [87]Coates RA, Rankin JG: Cost without benefit? The introduction of hepatitis B vaccine in Canada. Can Med Assoc J 1983, 128:1158-60.
  • [88]Kane MA: Global implementation of human papillomavirus (HPV) vaccine: lessons from hepatitis B vaccine. Gynecol Oncol 2010, 117(2):S32-5.
  • [89]Dickerson JB, Smith ML, Ory MG: Increasing uptake of Gardasil among American adolescents: Comparisons with the history of Hepatitis B vaccination. Hum Vaccin 2011, in press.
  • [90]Rothman SM, Rothman DJ: Marketing HPV vaccine: implications for adolescent health and medical professionalism. JAMA 2009, 302:781-6.
  • [91]Livingston J, Epstein S, Aronowitz R: Vaccine Timelines. In Three shots at prevention: The HPV vaccine and the politics of medicine's simple solutions. 1st edition. Edited by Wailoo K, Livingston J, Epstein S, Aronowitz R. Baltimore: Johns Hopkins University Press; 2010:xix-xxx.
  • [92]Scheifele D: Universal childhood hepatitis B vaccination: infants vs. preadolescents, the Canadian perspective. Pediatr Infect Dis J 1998, 17(Suppl 7):S35-7.
  • [93]Marra F, Cloutier K, Oteng B, Marra C, Ogilvie G: Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review. Pharmacoeconomics 2009, 27:127-47.
  • [94]Friedman AL, Shepeard H: Exploring the knowledge, attitudes, beliefs, and communication preferences of the general public regarding HPV: findings from CDC focus group research and implications for practice. Health Educ Behav 2007, 34:471-85.
  • [95]Lee PW, Kwan TT, Tam KF, Chan KK, Young PM, Lo SS, Cheung AN, Ngan HY: Beliefs about cervical cancer and human papillomavirus (HPV) and acceptability of HPV vaccination among Chinese women in Hong Kong. Prev Med 2007, 45:130-4.
  • [96]Rosenthal D, Dyson S, Pitts M, Garland S: Challenges to accepting a human papilloma virus (HPV) vaccine: a qualitative study of Australian women. Women Health 2007, 45:59-73.
  • [97]Scarinci IC, Garcés-Palacio IC, Partridge EE: An examination of acceptability of HPV vaccination among African American women and Latina immigrants. J Womens Health (Larchmt) 2007, 16:1224-33.
  • [98]Keating KM, Brewer NT, Gottlieb SL, Liddon N, Ludema C, Smith JS: Potential barriers to HPV vaccine provision among medical practices in an area with high rates of cervical cancer. J Adolesc Health 2008, 43(Suppl 4):S61-7.
  • [99]Kwan TT, Chan KK, Yip AM, Tam KF, Cheung AN, Young PM, Lee PW, Ngan HY: Barriers and facilitators to human papillomavirus vaccination among Chinese adolescent girls in Hong Kong: a qualitative-quantitative study. Sex Transm Infect 2008, 84:227-32.
  • [100]Toffolon-Weiss M, Hagan K, Leston J, Peterson L, Provost E, Hennessy T: Alaska Native parental attitudes on cervical cancer, HPV and the HPV vaccine. Int J Circumpolar Health 2008, 67:363-73.
  • [101]Vanslyke JG, Baum J, Plaza V, Otero M, Wheeler C, Helitzer DL: HPV and cervical cancer testing and prevention: knowledge, beliefs, and attitudes among Hispanic women. Qual Health Res 2008, 18:584-96.
  • [102]Bair RM, Mays RM, Sturm LA, Zimet GD: Acceptability of the human papillomavirus vaccine among Latina mothers. J Pediatr Adolesc Gynecol 2008, 21:329-34.
  • [103]Bingham A, Drake JK, LaMontagne DS: Sociocultural issues in the introduction of human papillomavirus vaccine in low-resource settings. Arch Pediatr Adolesc Med 2009, 163:455-61.
  • [104]Do H, Seng P, Talbot J, Acorda E, Coronado GD, Taylor VM: HPV vaccine knowledge and beliefs among Cambodian American parents and community leaders. Asian Pac J Cancer Prev 2009, 10:339-44.
  • [105]Harries J, Moodley J, Barone MA, Mall S, Sinanovic E: Preparing for HPV vaccination in South Africa: key challenges and opinions. Vaccine 2009, 27:38-44.
  • [106]Katz ML, Reiter PL, Heaner S, Ruffin MT, Post DM, Paskett ED: Acceptance of the HPV vaccine among women, parents, community leaders, and healthcare providers in Ohio Appalachia. Vaccine 2009, 27:3945-52.
  • [107]Madhivanan P, Krupp K, Yashodha MN, Marlow L, Klausner JD, Reingold AL: Attitudes toward HPV vaccination among parents of adolescent girls in Mysore, India. Vaccine 2009, 27:5203-8.
  • [108]Marlow LA, Wardle J, Waller J: Attitudes to HPV vaccination among ethnic minority mothers in the UK: an exploratory qualitative study. Hum Vaccin 2009, 5:105-10.
  • [109]Wong LP: HPV information needs, educational messages and channel of delivery preferences: views from developing country with multiethnic populations. Vaccine 2009, 27:1410-5.
  • [110]Krupp K, Marlow LA, Kielmann K, Doddaiah N, Mysore S, Reingold AL, Madhivanan P: Factors associated with intention-to-recommend human papillomavirus vaccination among physicians in Mysore, India. J Adolesc Health 2010, 46:379-84.
  • [111]Kaler A: Health interventions and the persistence of rumour: the circulation of sterility stories in African public health campaigns. Soc Sci Med 2009, 68:1711-9.
  • [112]Dugas M, Dubé E, Kouyaté B, Sanou A, Bibeau G: Portrait of a lengthy vaccination trajectory in Burkina Faso: from cultural acceptance of vaccines to actual immunization. BMC Int Health Hum Rights 2009, 9(Suppl 1):S9. BioMed Central Full Text
  • [113]Sherris J, Friedman A, Wittet S, Davies P, Steben M, Saraiya M: Chapter 25: Education, training, and communication for HPV vaccines. Vaccine 2006, 24(Suppl 3):210-8.
  • [114]Program for Appropriate Technology in Health (PATH): Introducing HPV vaccines in developing countries: overcoming the challenges. [http://www.path.org/files/RH_hpv_intro.pdf] webcite
  • [115]McCarthy C: Toward a Definition of Interiority. Volume 8. Space and Culture; 2005::112-125.
  • [116]Stanley M: Human papillomavirus vaccines versus cervical cancer screening. Clin Oncol (R Coll Radiol) 2008, 20:388-94.
  • [117]Mackroth MS, Irwin K, Vandelaer J, Hombach J, Eckert LO: Immunizing school-age children and adolescents: experience from low- and middle-income countries. Vaccine 2010, 28:1138-47.
  • [118]Ogilvie GS, Remple VP, Marra F, McNeil SA, Naus M, Pielak KL, Ehlen TG, Dobson SR, Money DM, Patrick DM: Parental intention to have daughters receive the human papillomavirus vaccine. CMAJ 2007, 177:1506-12.
  • [119]Watson M, Shaw D, Molchanoff L, McInnes C: Challenges, lessons learned and results following the implementation of a human papilloma virus school vaccination program in South Australia. Aust N Z J Public Health 2009, 33:365-70.
  • [120]European Cervical Cancer Association (ECCA): HPV Vaccination Across Europe. [http:/ / www.ecca.info/ fileadmin/ user_upload/ HPV_Vaccination/ ECCA_HPV_Vaccination_April_2009.pdf] webcite
  • [121]Stöckl A: Public discourses and policy making: the HPV vaccination from the European perspective. In Three shots at prevention: The HPV vaccine and the politics of medicine's simple solutions. 1st edition. Edited by Wailoo K, Livingston J, Epstein S, Aronowitz R. Baltimore: Johns Hopkins University Press; 2010:254-269.
  • [122]Humiston SG, Rosenthal SL: Challenges to vaccinating adolescents: vaccine implementation issues. Pediatr Infect Dis J 2005, 24:S134-40.
  • [123]Hernandez G, Nestor C: Educating teens about vaccines. J Pediatr Health Care 2006, 20:342-9.
  • [124]Department of Health and Wellness: HPV Immunization Launched. [http://www.gov.ns.ca/news/details.asp?id=20070620002] webcite
  • [125]Department of Health and Wellness: School Immunization Schedule. [http://www.gov.ns.ca/hpp/publications/13153_SchoolImmunizationSchedule_En.pdf] webcite
  • [126]Lippman A, Melnychuk R, Shimmin C, Boscoe M: Human papillomavirus, vaccines and women's health: questions and cautions. CMAJ 2007, 177:484-7.
  • [127]Haas M, Ashton T, Blum K, Christiansen T, Conis E, Crivelli L, Lim MK, Lisac M, Macadam M, Schlette S: Drugs, sex, money and power: an HPV vaccine case study. Health Policy 2009, 92:288-95.
  • [128]MacDonald N, Hébert PC: Human papillomavirus vaccine: waiting for a miracle. CMAJ 2007, 177:433-435.
  • [129]Franco EL, Bosch FX, Cuzick J, Schiller JT, Garnett GP, Meheus A, Wright TC: Chapter 29: Knowledge gaps and priorities for research on prevention of HPV infection and cervical cancer. Vaccine 2006, 24:S3/242-9.
  文献评价指标  
  下载次数:5次 浏览次数:23次